Project Grant R01AR083410
Award Date
9/10/24
Completion Date
7/31/29
Dollars Obligated
$595K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37232, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $361,300 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of North Carolina at Chapel Hill. The goal of this 2-year exploratory/developmental project is to use high-throughput small molecule screening and CRISPR screening technologies to identify signaling pathways and therapeutic targets for disease modification in osteoarthritis...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,657,392 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Pittsburgh. The grant funds research to repurpose FDA-approved drugs for the treatment of osteoarthritis (OA) using high-throughput screening in microphysiological models. The project aims to define the capacity of FDA-approved drugs to reverse cartilage-driven and inflammation-driven OA...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,288,152 to Tufts University School of Medicine to develop a novel screening approach called "JOINTSEQ" for identifying nanoparticles (NPs) that can precisely target specific cell types in the osteoarthritis (OA) joint environment. The project aims to create a library of...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to identify peptides that preferentially localize to osteoarthritic (OA) joints after intravenous injection and leverage these peptides to develop targeted OA drug carriers. The $208,627 award, granted on Jul 11, 2024, will fund research activities at the University of Florida and the...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a programmable siRNA-based therapeutic platform for gene silencing in the skin. The $249,000 award supports research at the University of Massachusetts Medical School to systematically evaluate the safety and efficacy of selective JAK1 silencing by therapeutic siRNA in mouse models...
This $578,944 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The primary objective is to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The research aims to identify new and fine-map known genetic loci associated with OA and total joint replacement, disentangle OA heterogeneity by...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $618,629 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado to establish a new "microphysiological joint-on-chip" system. The objective is to create a realistic human joint model that can support mechanistic study of arthritic diseases and rapid testing of candidate treatments. The researchers plan to develop...